554 related articles for article (PubMed ID: 35292771)
1. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.
Petroni G; Buqué A; Coussens LM; Galluzzi L
Nat Rev Drug Discov; 2022 Jun; 21(6):440-462. PubMed ID: 35292771
[TBL] [Abstract][Full Text] [Related]
2. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
3. The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors.
Takkenkamp TJ; Jalving M; Hoogwater FJH; Walenkamp AME
Endocr Relat Cancer; 2020 Sep; 27(9):R329-R343. PubMed ID: 32590336
[TBL] [Abstract][Full Text] [Related]
4. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
Weng CY; Kao CX; Chang TS; Huang YH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance.
Peng J; Yin X; Yun W; Meng X; Huang Z
Cancer Lett; 2023 Apr; 559():216108. PubMed ID: 36863506
[TBL] [Abstract][Full Text] [Related]
7. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
8. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.
Ahn R; Ursini-Siegel J
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807608
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Wang S; Xie K; Liu T
Front Immunol; 2021; 12():690112. PubMed ID: 34367148
[TBL] [Abstract][Full Text] [Related]
10. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy.
Chen S; Duan H; Sun G
Biomed Pharmacother; 2023 Aug; 164():114963. PubMed ID: 37269814
[TBL] [Abstract][Full Text] [Related]
11. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy?
Mauri D; Tsiouris S; Gkoura S; Gazouli I; Ntellas P; Amylidis A; Kampletsas L; Fotopoulos A
Cancer Treat Res Commun; 2021; 28():100441. PubMed ID: 34404012
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
14. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
Hu-Lieskovan S; Malouf GG; Jacobs I; Chou J; Liu L; Johnson ML
Future Oncol; 2021 Apr; 17(11):1401-1439. PubMed ID: 33475012
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in non-small cell lung cancer harbouring driver mutations.
Addeo A; Passaro A; Malapelle U; Banna GL; Subbiah V; Friedlaender A
Cancer Treat Rev; 2021 May; 96():102179. PubMed ID: 33798954
[No Abstract] [Full Text] [Related]
16. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity.
Donlon NE; Power R; Hayes C; Reynolds JV; Lysaght J
Cancer Lett; 2021 Apr; 502():84-96. PubMed ID: 33450360
[TBL] [Abstract][Full Text] [Related]
18. Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard CL; Delyon J; Wicky A; Homicsko K; Cuendet MA; Michielin O
Cancer Treat Rev; 2021 Dec; 101():102227. PubMed ID: 34656019
[TBL] [Abstract][Full Text] [Related]
19. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Giannone G; Ghisoni E; Genta S; Scotto G; Tuninetti V; Turinetto M; Valabrega G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575899
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.
Liu C; Wang M; Xu C; Li B; Chen J; Chen J; Wang Z
J Immunol Res; 2021; 2021():8970173. PubMed ID: 34877360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
